

**The report of launch joint clinical research on HIROTSU BIO SCIENCE's
High accuracy "N-NOSE" cancer screening test using nematodes.**

We report here that HIROTSU BIO SCIENCE INC. (Head office: Minato-ku, Tokyo, President & CEO: Takaaki Hirotsu; hereafter referred to as HIROTSU BIO) and Saitama Medical University International Medical Center (Hospital Director: Isamu Koyama) have launched joint clinical research for "N-NOSE" cancer screening test using nematodes.

Saitama Medical University International Medical Center is a hospital for cancer treatment cooperation, which is dedicated to highly specialized medical care for cancer. Especially, the department of medical gastroenterology (Prof. Shomei Ryozaawa) of the Center is highly evaluated as endoscope treatment technique for cancer internationally. By this cooperation, the research results intended gastric cancer, colon cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, and esophageal cancer were expected.

The aim and the content for this research

Cancer has been the biggest single killer in Japan since 1981; one in two Japanese people have undergone cancer; one in three have died from cancer. It is reported that early detection is important for the treatment of cancer, however the medical examination rate of a cancer screening test remains in a low level. The reason of the low examination rate of a cancer test should be derived from the pain of traditional cancer screenings, much time for undergoing the tests, and high cost. A less expensive, highly accurate, and non-invasive cancer screening test is required, and many researchers aim to develop cancer biomarkers throughout the world. Our study tries to establish an improved cancer screening test by utilizing the olfaction of nematodes, namely N-NOSE.

Inquiry Recipient

HIROTSU BIO SCIENCE INC.

2F Forum Bldg., 2-24-11 Minamiaoyama, Minato-ku, Tokyo 107-0062, Japan

E-mail: press@hbio.jp